cefpodoxime reference
Reference image
(cefpodoxime · DailyMed)
Registered Kenya · PPB

NEPODOX 50

CEFPODOXIME FOR ORAL SUSPENSION USP

H2016/CTD3714/433 50 MG NEW/INNOVATOR antiinfectives for systemic use INN generic

What it does

Cefpodoxime is an antibiotic used to treat bacterial infections.

Commonly used for: bacterial infections, respiratory tract infections, skin infections, urinary tract infections

Read more in plain English ↓

Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.

Ask about this medicine

Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.

Hard to find? We help patients in Kenya source rare medicines. We don't sell or dispense medicines - licensed pharmacies do.

Source this medicine

Registration & product details

Registration no.
H2016/CTD3714/433
Registration date
-
Expiry date
-
Status
Registered
Active ingredient
CEFPODOXIME FOR ORAL SUSPENSION USP
Dosage form
50 MG
Strength
-
Pack size
1 BOTTLE
Therapeutic class
NEW/INNOVATOR
ATC class (WHO)
J01DD - Third-generation cephalosporins
RxNorm RxCUI
20489
Manufacturer / MAH
Nairobi Enterprises
Country of origin
FOREIGN
Manufacturer location
JWW2+25R, Old Mombasa Rd, Nairobi. Shiv business park, Opposite SGR Nairobi terminus-old Mombasa road , Warehouse NO-15, Nairobi, Kenya

Source: Pharmacy and Poisons Board · fetched 2026-01-28 20:32:45 · updated 2026-07-26 11:23:27

Disclaimer: This information is sourced from Pharmacy and Poisons Board (Kenya). Always consult a qualified healthcare professional before using any medication.

About this medicine

Cefpodoxime is an antibiotic used to treat bacterial infections.

What it treats

  • bacterial infections
  • respiratory tract infections
  • skin infections
  • urinary tract infections

How it works

Cefpodoxime works by stopping the growth of bacteria, helping the body to fight off infections.

Who it's for

Cefpodoxime is for adults and children who have certain bacterial infections.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

Clinical monograph: cefpodoxime

BNF-referenced

Cefpodoxime is a third-generation cephalosporin antibiotic that is effective against a wide range of Gram-positive and Gram-negative bacteria. It is particularly noted for its stability against beta-lactamase enzymes, which makes it a suitable option for treating infections caused by organisms resistant to other penicillins and cephalosporins. However, it is not effective against certain bacteria such as Pseudomonas aeruginosa, Enterococcus, and Bacteroides fragilis.

Indications

  • Respiratory tract infections
  • Urinary tract infections
  • Skin and soft tissue infections
  • Otitis media

Dosage

Children: Refer to the BNF for Children for specific paediatric dosing recommendations.

Adults: Refer to the BNF for specific dosing guidelines.

Mechanism of action

Cefpodoxime exerts its bactericidal effect by inhibiting cell wall synthesis. The active metabolite binds preferentially to penicillin-binding protein 3, which leads to the inhibition of peptidoglycan production, the main component of bacterial cell walls. This mechanism is particularly effective against various Gram-positive and Gram-negative bacteria, enhancing its therapeutic utility in treating infections.

Pharmacodynamics

Cefpodoxime demonstrates effectiveness against most Gram-positive and Gram-negative bacteria, with notable exceptions including Pseudomonas aeruginosa, Enterococcus, and Bacteroides fragilis. Its ability to remain stable in the presence of beta-lactamase enzymes allows it to target bacteria that are otherwise resistant to beta-lactam antibiotics.

Pharmacokinetics

Cefpodoxime is well absorbed after oral administration, with its bioavailability enhanced by the presence of food. It is distributed widely in body tissues and fluids, with a significant volume of distribution. Cefpodoxime is primarily eliminated via renal excretion, with a half-life sufficient for twice-daily dosing in most cases. The active metabolite contributes to the antimicrobial activity and is also eliminated through renal pathways.

Adverse effects

  • Diarrhea
  • Nausea
  • Vomiting
  • Rash
  • Allergic reactions
  • Elevated liver enzymes

Precautions

  • Use with caution in patients with renal impairment
  • Monitor for signs of superinfection
  • Assess for history of penicillin allergy

Pregnancy

Cefpodoxime is classified as pregnancy category B. Animal studies have not demonstrated a risk to the fetus, but there are no adequate and well-controlled studies in pregnant women. It should be used during pregnancy only if clearly needed.

Breast-feeding

Cefpodoxime is excreted in breast milk. Caution is advised when administering to nursing mothers, as adverse effects on the infant are possible.

Storage

Store at room temperature, away from moisture and heat. Keep out of reach of children.

Formulations

  • Tablets
  • Oral suspension

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

Molecular reference: cefpodoxime

PubChem CID 6335986

Molecular formula: C15H17N5O6S2

Mechanism of action

Cefpodoxime is active against a wide spectrum of Gram-positive and Gram-negative bacteria. Cefpodoxime is stable in the presence of beta-lactamase enzymes. As a result, many organisms resistant to penicillins and cephalosporins, due to their production of beta-lactamase, may be susceptible to cefpodoxime. Cefpodoxime is inactivated by certain extended spectrum beta-lactamases. The bactericidal activity of cefpodoxime results from its inhibition of cell wall synthesis. The active metabolite of cefpodoxime binds preferentially to penicillin binding protein 3, which inhibits production of peptidoglycan, the primary constituent of bacterial cell walls.

Pharmacodynamics

Cefpodoxime is shown to be effective against most Gram positive and Gram negative bacteria, except <i>Pseudomonas aeruginosa</i>, <i>Enterococcus</i>, and <i>Bacteroides fragilis</i>.

Source: PubChem (NCBI) · pathways from PathBank, Reactome, WikiPathways & PharmGKB.

This drug in other countries

The same active ingredient registered across other registries we cover - including different brands.